Study: AMD Gene Therapy Demonstrates Vision Stabilization Study: AMD Gene Therapy Demonstrates Vision Stabilization
An early gene therapy trial reported maintenance of vision, reduced retinal inflammation, and detectable therapeutic protein levels 9 months after treatment for age-related macular degeneration.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - August 1, 2023 Category: Drugs & Pharmacology Tags: Ophthalmology News Source Type: news
Sticker Shock: Ophthalmic Bevacizumab Biosimilar Could Drive Up Costs
(MedPage Today) -- SEATTLE -- Availability of a bevacizumab (Avastin) biosimilar for ophthalmic use could have the unintended consequence of driving up the cost of treating retinal disease with angiogenesis inhibitors, according to an economic... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 1, 2023 Category: American Health Source Type: news
Pegcetacoplan-Related Eye Inflammation: The Search Is on for Answers
(MedPage Today) -- SEATTLE -- Reports of unexpected panuveitis and retinal occlusive vascular disease associated with pegcetacoplan (Syfovre) treatment has triggered a search for answers by ophthalmologists and the drug's manufacturer.
Since... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 31, 2023 Category: American Health Source Type: news
Stem Cell Therapies For Retinal Disorders Are A Sight For Sore Eyes
There are at least ten ongoing clinical trials for stem cell therapies in vision loss. We will delve into one of the preclinical studies in this piece. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 29, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease 5%, driven by lower...
Source: Roche Investor Update - July 27, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Basel, 27 July 2023Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease ...
Source: Roche Media News - July 27, 2023 Category: Pharmaceuticals Source Type: news
Blue-light filtering spectacles probably make no difference to eye strain, eye health or sleep quality
Spectacles that are marketed to filter out blue light probably make no difference to eye strain caused by computer use or to sleep quality, according toa Cochrane review of 17 randomised controlled trials of the best available evidence so far. Nor did the review, led by authors from the University of Melbourne and published in the Cochrane Database of Systematic Reviews, find any evidence that blue-light filtering lenses protect against damage to the retina, the light-sensitive tissue at the back of the eye.Blue-light filtering lenses, also known as blue-light blocking spectacles, have been increasingly prescribed or rec...
Source: Cochrane News and Events - July 26, 2023 Category: Information Technology Authors: Muriah Umoquit Source Type: news
New clinical and real-world data for Roche ’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss
Late-breaking post-hoc data indicateVabysmo leads to less fibrosis, which may negatively impact vision, thanaflibercept in people with diabetic macular edema (DME)Real-world data reinforce that first-lineVabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for people withneovascular or ‘wet’ age-related macular degeneration (nAMD) and DMEClinical data reiterateVabysmo ’s positive anatomical outcomes, including reduced blood vessel leakage in the macula and greater and faster retinal fluid controlVabysmo is currently approved in over 70 countries to treatnAMD and DME, with...
Source: Roche Media News - July 20, 2023 Category: Pharmaceuticals Source Type: news
New clinical and real-world data for Roche ’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss
Late-breaking post-hoc data indicateVabysmo leads to less fibrosis, which may negatively impact vision, thanaflibercept in people with diabetic macular edema (DME)Real-world data reinforce that first-lineVabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for people withneovascular or ‘wet’ age-related macular degeneration (nAMD) and DMEClinical data reiterateVabysmo ’s positive anatomical outcomes, including reduced blood vessel leakage in the macula and greater and faster retinal fluid controlVabysmo is currently approved in over 70 countries to treatnAMD and DME, with...
Source: Roche Investor Update - July 20, 2023 Category: Pharmaceuticals Source Type: news
Retinal OCT Shows Promise as Diagnostic Aid for Mild Cognitive Impairment
(MedPage Today) -- Aided by artificial intelligence, analysis of retinal images and related data identified condition-specific features that distinguished patients with mild cognitive impairment from those with normal cognition, a prospective study... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - July 17, 2023 Category: Psychiatry Source Type: news
Retinal Thickness a New Predictor of MS Disability? Retinal Thickness a New Predictor of MS Disability?
Measuring the thickness of the retina shortly after diagnosis in multiple sclerosis patients could predict their risk of accumulated disability later in the disease course, say Austrian researchers.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 14, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Does Aspartame Cause Cancer or Is It Safe to Consume? What to Know About the Sweetener
The World Health Organization’s cancer agency has deemed the sweetener aspartame — found in diet soda and countless other foods — as a “possible” cause of cancer, while a separate expert group looking at the same evidence said it still considers the sugar substitute safe in limited quantities.
The differing results of the coordinated reviews were released early Friday. One came from the International Agency for Research on Cancer, a special branch of the WHO. The other report was from an expert panel selected by WHO and another U.N. group, the Food and Agriculture Organization.
The Lyon, Franc...
Source: TIME: Health - July 14, 2023 Category: Consumer Health News Authors: Maria Cheng and Jonel Aleccia / AP Tags: Uncategorized Diet & Nutrition wire Source Type: news
Does Aspartame Cause Cancer or Is It Safe to Consume? The Latest Evidence About the Artificial Sweetener
The World Health Organization’s cancer agency has deemed the sweetener aspartame — found in diet soda and countless other foods — as a “possible” cause of cancer, while a separate expert group looking at the same evidence said it still considers the sugar substitute safe in limited quantities.
The differing results of the coordinated reviews were released early Friday. One came from the International Agency for Research on Cancer, a special branch of the WHO. The other report was from an expert panel selected by WHO and another U.N. group, the Food and Agriculture Organization.
The Lyon, Franc...
Source: TIME: Health - July 14, 2023 Category: Consumer Health News Authors: Maria Cheng and Jonel Aleccia / AP Tags: Uncategorized Diet & Nutrition wire Source Type: news
Quadria Capital plans ₹1.3k cr invesment in Maxivision Eye hospital
Founded in 1996 by renowned ophthalmologist Kasu Prasad Reddy, Maxivision was subsequently acquired by GSK Velu in 2010.Maxivision operates 42 centres in five states across South and West India, with a leadership position in Andhra Pradesh and Telangana. The company offers a full suite of eye care services, including cataract surgery, LASIK and ReLEx Smile treatments, treatments for retinal issues and glaucoma, oculoplasty, as well as neonatal and paediatric eye care. (Source: The Economic Times)
Source: The Economic Times - July 12, 2023 Category: Consumer Health News Source Type: news
Coffee and the Brain; Detecting Prodromal Parkinson's; Functional Seizure Clinics
(MedPage Today) -- Mechanisms related specifically to coffee -- not just caffeine -- may be why the beverage helps people stay alert. (Frontiers in Neuroscience)
Adding retinal layer thickness to the 2017 McDonald criteria improved diagnostic... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - July 11, 2023 Category: Neurology Source Type: news
